Physician profile
Remi Mathews
NPI 1407054794
$4,834.75
in general payments reported to CMS, 2019-2025
32 companies · $1,120 in 2025
The $1,120 reported for 2025 was more than what 88% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $139 · 2020: $41.09 · 2021: $570 · 2022: $727 · 2023: $1,194 · 2024: $1,045 · 2025: $1,120.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,358.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,358.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $926.84 | 2021-2025 | |
| Novo Nordisk INC | $646.25 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $448.76 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $435.63 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $311.91 | 2021-2025 | Airsupra, Breztri |
| Exact Sciences Corporation | $262.99 | 2023-2025 | Cologuard Collection Kit |
| Phathom Pharmaceuticals, INC. | $180.42 | 2024-2025 | Voquezna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $173.83 | 2021-2025 | Xifaxan, Trulance |
| Janssen Pharmaceuticals, INC | $170.06 | 2023-2025 | Xarelto, Spravato |
| Merck Sharp & Dohme LLC | $152.85 | 2022-2025 | Gardasil 9, Capvaxive, Vaxneuvance |
| E.R. Squibb & Sons, L.L.C. | $147.67 | 2021-2023 | Eliquis |
| Sanofi-Aventis U.S. LLC | $146.95 | 2021-2023 | |
| Glaxosmithkline, LLC. | $128.89 | 2019-2023 | Trelegy Ellipta, Bexsero, Shingrix |
| Actelion Pharmaceuticals US, INC. | $87.77 | 2024-2025 | Uptravi, Opsumit |
| Astellas Pharma US INC | $84.73 | 2022-2024 | Veozah, Myrbetriq |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $66.67 | 2023-2025 | |
| Kowa Pharmaceuticals America, INC. | $61.07 | 2022-2025 | Seglentis, Zoryve |
| Abbott Laboratories | $45.56 | 2024 | Freestyle Libre 3 |
| Sanofi Pasteur INC. | $45.52 | 2024 | |
| Allergan, INC. | $41.09 | 2020 | |
| Amgen INC. | $34.92 | 2025 | Otezla, Repatha |
| Vbi Vaccine (Delaware) INC. | $28.04 | 2022 | |
| Alnylam Pharmaceuticals INC. | $27.84 | 2021 | |
| Amarin Pharma, INC. | $24.88 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $24.68 | 2024 | Caplyta |
| Eisai INC. | $22.01 | 2021 | |
| Vanda Pharmaceuticals INC. | $21.19 | 2025 | Fanapt |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.06 | 2022 | |
| Evoke Pharma, INC. | $18.20 | 2025 | |
| Biohaven Pharmaceuticals, INC. | $17.67 | 2021 | |
| Seqirus USA INC | $14.96 | 2025 | Fluad, Flucelvax |
| Lifescan, INC. | $14.84 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Remi Mathews listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.